IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Tryptamine Therape Ordf

CUSIP: Q9240A100 | 1 institutional holders

Quarters

Q3 2025Q2 2025Q4 2024
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q3 2025

Financially Speaking Inc361,600
0.0% of portfolio›$9.8K
StyleTurnoverLocationFiled
Financially Speaking Inc
361,600$9.8K0.0%ETFHighGreenwood Village, CO2025-11-06